^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclosporin A microemulsion

    i
    Other names: OLO400, OLO-400, OLO 400
    Company:
    Generic mfg.
    Drug class:
    Calcineurin inhibitor
    Related drugs:
    6d
    Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Boston Children's Hospital | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial primary completion date
    |
    TERT (Telomerase Reverse Transcriptase) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • DKC1 (Dyskerin Pseudouridine Synthase 1) • ZCCHC8 (Zinc Finger CCHC-Type Containing 8) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion
    21d
    Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies. (PubMed, Mediterr J Hematol Infect Dis)
    Routine TDM was most frequently used for classical agents (methotrexate, cyclosporin A), antifungals, and antibiotics, but substantial interest was reported for targeted therapies, including BCL-2 inhibitors, BCR-ABL tyrosine kinase inhibitors, FLT3 inhibitors, and Bruton tyrosine kinase inhibitors. While firmly established for classical agents and anti-infectives, clinicians express growing interest in extending TDM to targeted therapies. Optimizing turnaround times, expanding assay availability, and integrating pharmacokinetics-informed dosing into clinical trials may further clarify the role of TDM within precision medicine approaches in hematology.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    methotrexate • cyclosporin A microemulsion
    21d
    Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • cyclosporin A microemulsion
    21d
    NCI-2019-03188: Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=120, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • sirolimus • fludarabine IV • thiotepa • busulfan • cyclosporin A microemulsion • methotrexate IV
    21d
    Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jun 2027 --> Dec 2027 | Trial primary completion date: Jun 2027 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib) • sirolimus • fludarabine IV • cyclosporin A microemulsion
    1m
    Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (clinicaltrials.gov)
    P2, N=60, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jan 2028 --> Mar 2029 | Trial primary completion date: Feb 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim)
    2ms
    Natural Product Modulators of Protein-Protein Interactions: A Comprehensive Review. (PubMed, Phytochem Anal)
    Collectively, these modulators demonstrate PPI druggability and provide chemical probes and lead scaffolds for therapeutic development in cancer, neurodegeneration, infectious disease, and immune disorders.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    sirolimus • cyclosporin A microemulsion • R-(-)-gossypol (AT 101)
    2ms
    Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies (clinicaltrials.gov)
    P2/3, N=64, Recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology
    New P2/3 trial
    |
    Jakafi (ruxolitinib) • sirolimus • cyclosporin A microemulsion • Orencia (abatacept)
    3ms
    A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia (clinicaltrials.gov)
    P3, N=210, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    cyclosporin A microemulsion • Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    3ms
    Inhibition of LDHA promotes GSDME-dependent pyroptosis by activating RIG-I-like receptor signaling. (PubMed, Apoptosis)
    Here, a novel combination therapy consisting of the calcineurin inhibitor cyclosporine A (CsA) and the flavone-naphthalimide-polyamine derivative 6c was identified...Finally, combination of CsA and 6c suppressed tumor growth and pulmonary metastasis in vivo. Overall, our study suggests a novel synergistic treatment combination with a comprehensive mechanistic exploration, demonstrating that it is a promising strategy for HCC treatment via targeting RIG-I-like receptor signaling.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • IFIH1 (Interferon Induced With Helicase C Domain 1) • GSDME (Gasdermin E) • IRF3 (Interferon Regulatory Factor 3) • TBK1 (TANK Binding Kinase 1)
    |
    cyclosporin A microemulsion
    3ms
    Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Boston Children's Hospital | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    TERT (Telomerase Reverse Transcriptase) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • DKC1 (Dyskerin Pseudouridine Synthase 1) • ZCCHC8 (Zinc Finger CCHC-Type Containing 8) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion
    3ms
    Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (clinicaltrials.gov)
    P2, N=31, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    MLL rearrangement
    |
    clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion